NDATOPICALCREAM
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
DENAVIR (penciclovir) by Viatris (2) is dna polymerase inhibitors [moa]. First approved in 1996.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DENAVIR (penciclovir) is a topical nucleoside analog DNA polymerase inhibitor approved in 1996 for herpesvirus infections. It is formulated as a cream applied directly to affected skin lesions and works by inhibiting viral DNA replication. The drug is indicated for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.
$0.889MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D utilization signals a contracting revenue base and reduced team expansion potential.
Mechanism of Action
DNA Polymerase Inhibitors
Pharmacologic Class:
Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
Started Feb 2012
76 enrolled
Herpes Labialis
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Started Dec 2008
126 enrolled
Cold Sore
Career Relevance
DENAVIR offers limited career growth opportunity due to its LOE approaching status and minimal current job openings (0 linked positions). Professionals assigned to this product would focus on generic transition management, competitive pricing strategies, and market share defense rather than growth initiatives.
Worked on DENAVIR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.